Pfizer recalls more than half-million vials of Protonix

Pfizer has recalled more than half a million vials of heartburn med Protonix.

Pfizer has recalled more than half a million vials of Protonix, its injected gastrointestinal med that has been distinguished in recent years by the litigation surrounding it.

The New York drugmaker actually initiated the voluntary recall in November because of a possibility the proton-pump inhibitor might be subpotent, but the FDA only last week deemed it a class III recall. Pfizer recalled 8 lots of Protonix, comprising 582,165 vials.

A month later, India’s Aurobindo recalled 29,800 vials of its generics version of the drug.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

While there are generics of Protonix on the market now, there weren’t in 2007 when Teva and Sun Pharma took a chance and launched their at-risk generics of the med. They were taking a chance they could win a patent challenge against the drug's then-marketer Wyeth. It was no-go, however, when in 2010 a jury nixed that possibility with the decision that the Protonix patent was valid, leaving the two on the hook for big bucks.  

Pfizer and Takeda, which shared Protonix, in 2013, reached a $2.15 billion settlement over infringement on the 2011 patent for the acid reflux medication, with Sun shouldering about $550 million of the cost.

Then last year, Pfizer had to turn around and pay out $786 million in a settlement with the Justice Department to get beyond claims that Wyeth overcharged Medicaid for the heartburn med. Pfizer inherited the case with acquisition of Wyeth in 2009.


Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.